Regeneron Pharmaceuticals Chooses Veeva Vault CRM to Enhance Commercial Evidence Generation

In a significant move to enhance their commercial operations, Regeneron Pharmaceuticals has announced the adoption of Veeva Vault CRM on a global scale. The integration of Vault CRM aims to leverage AI-driven field interactions to generate actionable commercial evidence, uncover hidden barriers to treatment adoption, and ensure timely access to crucial medications for patients who need them.

Ryan Steinberger, Regeneron's Executive Vice President and Chief Digital Technology Officer, expressed enthusiasm about the strategic partnership with Veeva, noting that Vault CRM will provide their commercial teams with a more connected platform. This change is expected to streamline access to necessary information, facilitating more effective decision-making across the organization.

Matt Farrell, Veeva's Commercial Strategy President, emphasized the company's commitment to supporting Regeneron in their mission of developing innovative treatments for patients facing severe illnesses. By adopting Vault CRM, Regeneron is poised to enhance its efforts in delivering essential medications to those in need.

Vault CRM is an integral part of the Vault CRM Suite, which serves as a technical foundation for commercial execution. One of its standout features is the Agent Call Report. This functionality transforms each field interaction into a source of commercial evidence, capturing valuable insights that were previously lost due to compliance issues or cumbersome dropdown menus.

The collaboration between Veeva and Regeneron is rooted in shared values of innovation and excellence. Veeva Systems, recognized as the leading cloud platform for life sciences, caters to over 1,500 clients, from major pharmaceutical companies to emerging biotech firms. This partnership reflects Veeva's commitment to balancing the interests of stakeholders, including clients, employees, shareholders, and the communities they serve.

The decision to select Vault CRM comes amid an evolving landscape in the biopharmaceutical industry, where the effective integration of technology in commercial activities is becoming increasingly crucial. Companies are recognizing the necessity of leveraging advanced digital tools to navigate complex market dynamics and enhance patient access to groundbreaking therapies.

As Regeneron implements Veeva Vault CRM, it will not only improve its internal processes but also contribute to a broader understanding of the barriers that prevent patients from receiving necessary treatments. The ability to capture and analyze commercial evidence in real-time will facilitate more strategic decision-making, allowing Regeneron to refine its approach and optimize treatment pathways for patients.

In conclusion, the adoption of Veeva Vault CRM by Regeneron Pharmaceuticals marks a pivotal step in the biotechnology sector, emphasizing the importance of technology in fostering better healthcare outcomes. As both companies continue to align their strategies and innovations, there is potential for groundbreaking advancements in patient access and evidence generation within the pharmaceutical industry.